**The DEA's April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while broader rescheduling of all marijuana remains under review.** An administrative hearing on transferring marijuana from Schedule I to Schedule III concluded in mid-July 2026 after starting June 29, with the ALJ expected to issue a recommendation to the DEA Administrator. Opponents, including several states and advocacy groups, filed briefs against the change, citing concerns over medical use standards and abuse potential. A September 2026 appeals court ruling rejected efforts to block the April order, allowing the medical rescheduling to stand during litigation. Trader consensus reflects the extended timeline for a final rule on wider rescheduling, with post-hearing briefing and agency review still ahead and no firm publication date set.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato$809,958 Vol.
30 set 2026
30 settembre
3%
31 dicembre
16%
$809,958 Vol.
30 settembre
$679 Vol.
3%
31 dicembre
$199,708 Vol.
16%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The DEA's April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while broader rescheduling of all marijuana remains under review.** An administrative hearing on transferring marijuana from Schedule I to Schedule III concluded in mid-July 2026 after starting June 29, with the ALJ expected to issue a recommendation to the DEA Administrator. Opponents, including several states and advocacy groups, filed briefs against the change, citing concerns over medical use standards and abuse potential. A September 2026 appeals court ruling rejected efforts to block the April order, allowing the medical rescheduling to stand during litigation. Trader consensus reflects the extended timeline for a final rule on wider rescheduling, with post-hearing briefing and agency review still ahead and no firm publication date set.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercato aperto: Jul 31, 2026, 5:46 PM ET
Volume
$809,958Data di fine
1 gen 2027Mercato aperto
Jul 31, 2026, 5:46 PM ETRisolutore
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The DEA's April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while broader rescheduling of all marijuana remains under review.** An administrative hearing on transferring marijuana from Schedule I to Schedule III concluded in mid-July 2026 after starting June 29, with the ALJ expected to issue a recommendation to the DEA Administrator. Opponents, including several states and advocacy groups, filed briefs against the change, citing concerns over medical use standards and abuse potential. A September 2026 appeals court ruling rejected efforts to block the April order, allowing the medical rescheduling to stand during litigation. Trader consensus reflects the extended timeline for a final rule on wider rescheduling, with post-hearing briefing and agency review still ahead and no firm publication date set.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$809,958Data di fine
1 gen 2027Mercato aperto
Jul 31, 2026, 5:46 PM ETRisolutore
0x65070BE91...**The DEA's April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while broader rescheduling of all marijuana remains under review.** An administrative hearing on transferring marijuana from Schedule I to Schedule III concluded in mid-July 2026 after starting June 29, with the ALJ expected to issue a recommendation to the DEA Administrator. Opponents, including several states and advocacy groups, filed briefs against the change, citing concerns over medical use standards and abuse potential. A September 2026 appeals court ruling rejected efforts to block the April order, allowing the medical rescheduling to stand during litigation. Trader consensus reflects the extended timeline for a final rule on wider rescheduling, with post-hearing briefing and agency review still ahead and no firm publication date set.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti